SOP for Protocol Amendments and Regulatory Notifications

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-Protocol-Amendments-and-Regulatory-Notifications”
},
“headline”: “SOP for Protocol Amendments and Regulatory Notifications in Clinical Trials”,
“description”: “A regulatory-compliant SOP detailing the step-by-step process for managing clinical trial protocol amendments and regulatory notifications as per ICH GCP, WHO, FDA, EMA, and CDSCO requirements.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Published on 23/12/2025

Standard Operating Procedure for Protocol Amendments and Regulatory Notifications in Clinical Trials

Department	Clinical Research
SOP No.	CR/REG/002/2025
Supersedes	NA
Page No.	1 of 20
Issue Date	26/08/2025
Effective Date	01/09/2025
Review Date	01/09/2026

Table of Contents

Purpose

The purpose of this SOP is to describe the process for preparing, reviewing, submitting, and tracking clinical trial protocol amendments and associated regulatory notifications. This ensures compliance

with ICH GCP, GMP, WHO guidelines, and national regulatory authority requirements (FDA, EMA, MHRA, CDSCO, TGA).

Scope

This SOP applies to all clinical research staff, investigators, regulatory affairs personnel, and quality assurance teams involved in protocol amendments and regulatory notifications for ongoing or planned clinical trials. It covers both substantial amendments (those impacting patient safety, trial conduct, or data integrity) and non-substantial amendments.

Responsibilities

Principal Investigator (PI): Initiates protocol amendment requests and ensures scientific justification.
Regulatory Affairs Manager: Prepares and submits amendment packages to regulatory authorities and ethics committees.
Clinical Research Associate (CRA): Communicates changes to site staff and ensures implementation.
Quality Assurance Officer: Verifies compliance of amendments with regulatory requirements.
Head of Clinical Research: Approves protocol changes prior to submission.

Accountability

The Regulatory Affairs Head is accountable for ensuring all amendments and notifications are submitted accurately and within the defined timelines. Failure to notify may result in regulatory non-compliance, trial suspension, or penalties.

Procedure

1. Identification of Amendment Requirement
Determine if proposed changes qualify as substantial (e.g., changes to trial endpoints, dosage, inclusion/exclusion criteria) or non-substantial (e.g., administrative corrections).
Document rationale for amendment in an Amendment Request Form.

2. Preparation of Amendment Dossier
Update the Clinical Trial Protocol with tracked changes.
Revise associated documents (e.g., Informed Consent Form, Investigator’s Brochure).
Compile country-specific forms and cover letters.
Ensure updated safety information is included, if applicable.

3. Internal Review and Approval
Submit amendment dossier to QA for compliance review.
Obtain internal approvals from the Head of Clinical Research.
Maintain version control and document history.

4. Submission to Regulatory Authority and Ethics Committee
Submit amendment electronically via eCTD or as required by local authority.
Notify the Ethics Committee/IRB with complete amendment dossier.
Ensure acknowledgment of submission is filed in the Regulatory Communication Log.

5. Notification to Sites and Investigators
Provide site staff with revised protocol and training, if applicable.
Ensure investigators sign acknowledgment of receipt of updated documents.

6. Documentation and Archiving
File all amendment-related documents in the Trial Master File (TMF).
Maintain amendment tracking log for audit readiness.

Abbreviations

SOP: Standard Operating Procedure
PI: Principal Investigator
CRA: Clinical Research Associate
QA: Quality Assurance
eCTD: Electronic Common Technical Document
TMF: Trial Master File
EC/IRB: Ethics Committee/Institutional Review Board

Documents

Amendment Request Form (Annexure-1)
Amendment Tracking Log (Annexure-2)
Regulatory Communication Log (Annexure-3)

References

ICH E6(R2) Good Clinical Practice
US FDA Guidance on Protocol Amendments
EMA Clinical Trial Regulation (EU No. 536/2014)
WHO Good Clinical Practice Guidelines
CDSCO Clinical Trial Rules, India (2019)

Version: 1.0

Approval Section

Prepared By	Rajesh Kumar, Regulatory Affairs Specialist
Checked By	Sunita Reddy, QA Officer
Approved By	Dr. Anil Sharma, Head of Clinical Research

Annexures

Annexure-1: Amendment Request Form

Date	Protocol No.	Description of Amendment	Reason	Initiated By
01/09/2025	CTP-2025-01	Change in dosing frequency	Safety findings	Dr. Meera Joshi

Annexure-2: Amendment Tracking Log

Amendment No.	Date Submitted	Submitted To	Status	Remarks
01	05/09/2025	EMA	Under review	Additional safety data requested

Annexure-3: Regulatory Communication Log

Date	Authority	Query	Response	Responsible Person
12/09/2025	FDA	Clarification on inclusion criteria	Submitted revised section	Rajesh Kumar

Revision History

Revision Date	Revision No.	Revision Details	Reason for Revision	Approved By
26/08/2025	00	Initial version	New SOP creation	Head, Clinical Research

For more SOPs visit: Pharma SOP